Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Related Questions
For patients with modest hyperbilirubinemia (Tbili 2-3) due to chronic liver disease, but otherwise normal liver indices, would you consider still utilizing enfortumab vedotin for metastatic urothelial carcinoma?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
What is your preferred treatment for a patient with refractory metastatic upper tract urothelial carcinoma previously treated with adjuvant gemcitabine/cisplatin, enfortumab vedotin + pembrolizumab, docetaxel and sacituzumab govitecan?
How would do manage stage II/III Muscle invasive bladder cancer with large cell neuroendocrine histology?
Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?
Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for patients with muscle invasive bladder cancer?
Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
